Analysts Boost Targets for KalVista Ahead of Key Q4 Report, Citing Oral HAE Therapy Potential
TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.